Compare Crispr Therapeutics AG (CRSP) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs LYFT Inc — how do they compare? Crispr Therapeutics AG trades at $50.73 (market cap $5.06B), while LYFT Inc trades at $16.15 (market cap $5.90B). The key difference: LYFT Inc is the larger of the two by market cap, and LYFT Inc is more actively traded (9,741,129 versus 1,678,371). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and LYFT Inc for 47 Days on average.
| CRSP | LYFT | |
|---|---|---|
Market Cap | $5.06B | $5.90B |
Volume | 1,678,371 | 9,741,129 |
Sector | Health | Technology |
52-Week High | $74.92 | $24.57 |
52-Week Low | $44.34 | $12.65 |
Typical Hold Time | 77 Days | 47 Days |
Enterprise Value | $3.48B | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 6.59% over 24 hours amid bearish technical signals. The company shows negative profitability metrics with -4,101.26% net income margin and -$581.60M net loss for 2025, though Q2 2026 EPS beat expectations. Recent news highlights upcoming clinical data presentations and commercial progress with CASGEVY gene therapy. Cash flow remains negative from operations but positive overall due to financing activities.
While analyst consensus remains bullish with 57.9% buy ratings and $67.83 price target, significant execution risks persist. The stock faces pressure from sustained cash burn and competitive threats, but potential catalysts include upcoming clinical data readouts and CASGEVY revenue growth. Investors should weigh high-risk biotech volatility against breakthrough therapy potential.
Lyft trades at $16.13, up 2.35% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported strong revenue growth to $6.32B in 2025 and a net income of $2.84B, though recent quarterly EPS results have missed expectations. Positive developments include European expansion and a partnership with Sphere, while a $272.5M legal settlement poses a headwind.
The outlook is mixed; low P/E and P/S ratios suggest undervaluation, and analyst consensus targets $18.07, but execution risks and competitive pressures remain. Earnings consistency is key for sustained upside, with the stock offering value if growth momentum continues despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
